Pfizer Inc.

AI Score

XX

Unlock

26.38
0.19 (0.73%)
At close: Mar 21, 2025, 3:59 PM
0.73%
Created with Highcharts 11.4.309:30 AM12:45 PM04:00 PM25.752626.2526.526.75
Bid 26.1
Market Cap 149.48B
Revenue (ttm) 61.74B
Net Income (ttm) 7.78B
EPS (ttm) 1.41
PE Ratio (ttm) 18.71
Forward PE 9.16
Analyst Hold
Ask 26.12
Volume 53,113,049
Avg. Volume (20D) 38,618,061
Open 26.13
Previous Close 26.19
Day's Range 26.01 - 26.38
52-Week Range 24.48 - 31.54
Beta 0.54

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable an...

Sector Healthcare
IPO Date Jun 1, 1972
Employees 81,000
Stock Exchange NYSE
Ticker Symbol PFE
Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $31, which is an increase of 17.54% from the latest price.

Created with Highcharts 11.4.3StrongSellSellHoldBuyStrongBuy0102468
Price Target: $31
(17.54% upside)
Analyst Consensus: Hold
Stock Forecasts

Next Earnings Release

Pfizer Inc. is scheduled to release its earnings on Apr 29, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+1.54%
Shares of vaccine makers are trading higher after ... Unlock content with Pro Subscription
1 month ago
+2.2%
Shares of vaccine stocks are trading higher as the sector sees volatility amid Robert F. Kennedy Jr.'s nomination as HHS secretary. Sen. Senator Bill Cassidy said Kennedy committed to cooperation and would not remove vaccine information from the CDC website if confirmed.